BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 421202)

  • 1. Expression of cell-mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro.
    Pattillo RA; Story MT; Ruckert AC
    Cancer Res; 1979 Apr; 39(4):1185-92. PubMed ID: 421202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cellular phenotypes in tumor cyst and ascitic fluid from ovarian serous carcinoma.
    Harlozinska A; Bar JK; Richter R; Cislo M
    Acta Cytol; 1992; 36(6):869-74. PubMed ID: 1449024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Density distribution and antigenic characterization of cell subpopulations isolated from cystic fluids of ovarian serous neoplasms.
    Harłozińska A; Bar JK; Rabczyński J; Noworolska A; Richter R; Cisło M
    Anticancer Res; 1989; 9(1):161-6. PubMed ID: 2705745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes.
    Melioli G; Ferrari I; Casartelli G; Ragni N
    Gynecol Oncol; 1993 Mar; 48(3):301-7. PubMed ID: 8462898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
    Shi ZL
    Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor associated antigen in ovarian carcinoma.
    Negishi Y; Mutai Y; Akiya K; Fujiwara Y; Singh G
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):126-32. PubMed ID: 6199439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor markers in ovarian cancer: tumor-associated antigens.
    Barlow JJ; Bhattacharya M
    Semin Oncol; 1975 Sep; 2(3):203-9. PubMed ID: 827023
    [No Abstract]   [Full Text] [Related]  

  • 11. Carcinoembryonic antigen in human ovarian neoplasms.
    Marchand A; Fenoglio CM; Pascal R; Richart RM; Bennett S
    Cancer Res; 1975 Dec; 35(12):3807-10. PubMed ID: 1192434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of human ovarian tumor-associated antigens by sandwich enzyme immunoassay.
    Rao GS; Hanjani P
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):423-8. PubMed ID: 3279355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated immunity and blocking factor in ovarian carcinoma.
    Mitchell MS; Kohorn EI
    Obstet Gynecol; 1976 Nov; 48(5):590-7. PubMed ID: 980285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated antigen for cystadenocarcinomas of the ovary.
    Bhattacharya M; Barlow JJ
    Natl Cancer Inst Monogr; 1975 Oct; 42():25-32. PubMed ID: 825781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological reactivity of mucinous and serous ovarian adenocarcinomas.
    Harłozińska-Szmyrka A; Slesak B; Richter R; Rabczyński J; Cisło M
    Cancer Detect Prev; 1986; 9(3-4):347-58. PubMed ID: 3017557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
    Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
    Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
    Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
    Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
    Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms.
    van Nagell JR; Pletsch QA; Goldenberg DM
    Cancer Res; 1975 Jun; 35(6):1433-7. PubMed ID: 805659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.